Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Heart disease. Hearing loss. Addiction. Chronic pain. Alzheimer's. ALS. These are some of the areas where Eli Lilly, flush with cash from its GLP-1 drugs, wants to make big bets. These are the ...